Published in Cancer Weekly, July 28th, 1997
TLC D-99 currently is being studied in two Phase III clinical trials in metastatic breast cancer in the U.S. and in a third study in Europe. In the U.S., a single agent study is designed to compare TLC D-99 to conventional doxorubicin. The combination study compares the two drugs when each is administered with cyclophosphamide.
The primary end point of the studies is to demonstrate that TLC D-99 is significantly safer with regard to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.